This promotional information is intended for healthcare professionals based
in the UK.
If you are not a healthcare professional in the UK, click here.
For Prescribing and Adverse Event reporting information, click here.

ELIQUIS® (apixaban) is indicated for prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA), age ≥75 years, hypertension, diabetes mellitus, symptomatic heart failure (NYHA Class ≥II); treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults; and, prevention of venous thromboembolic events (VTE) in patients who have undergone elective hip or knee replacement surgery.

What’s new

ARISTOTLE Clinical Trial

ELIQUIS® offers superior reductions in the rates of stroke / systemic embolism AND major bleeding vs. warfarin, plus a significant reduction in all-cause mortality1

In patients with NVAF, ELIQUIS demonstrated:1

  • Superior risk reduction in stroke / systemic embolism vs. warfarin1*
  • Superior risk reduction in major bleeding vs. warfarin1*
  • Significant risk reduction in all-cause mortality vs. warfarin1*

Discover the data supporting ELIQUIS for the prevention of stroke and systemic embolism in patients with NVAF from the ARISTOTLE study

The full publication is available to read here†

FOOTNOTES

* The ARISTOTLE clinical trial was a randomised, double-blind, double-dummy, non-inferiority trial in 18,201 patients with NVAF and at least one other risk factor for stroke. Stroke / systemic embolism, including haemorrhagic, ischaemic or undetermined stroke, was the primary efficacy endpoint, major bleeding according to ISTH criteria was the primary safety outcome and all-cause mortality was a key secondary endpoint.1 Pre-specified hierarchical sequential testing was performed first on stroke / systemic embolism (primary efficacy endpoint) for non-inferiority, then for superiority, then on major bleeding, and finally, on death from any cause (secondary endpoint).1 The median duration of follow-up was 1.8 years.1

† This link is to a third-party site unaffiliated with the Pfizer / BMS Alliance. Please abide by the terms of use of the site.

ARR = Absolute Risk Reduction   CI = Confidence Interval   HR = Hazard Ratio   
ISTH = International Society on Thrombosis and
Haemostasis   N = Total number of patients in either the ELIQUIS group or the warfarin group   n = Number of patients with event   
NVAF = Non-Valvular Atrial Fibrillation   RRR = Relative Risk Reduction

REFERENCE

  1. Granger CB et al. N Engl J Med 2011; 365: 981–992.